Description:
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy
works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is
a type of treatment that uses drugs or other substances to identify and attack specific types
of tumor cells that may have less harm to normal cells. Genetic sequencing may help identify
these specific types of tumor cells in patients with non-small cell lung cancer.
Title
- Brief Title: Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
- Official Title: CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer
Clinical Trial IDs
- ORG STUDY ID:
CGI-068
- SECONDARY ID:
NCI-2014-00717
- SECONDARY ID:
CGI-068
- SECONDARY ID:
P30CA006927
- NCT ID:
NCT02132884
Conditions
- Malignant Pericardial Effusion
- Malignant Pleural Effusion
- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
Interventions
| Drug | Synonyms | Arms |
|---|
| targeted therapy | | Arm B (genetic sequencing and targeted therapy) |
Purpose
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy
works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is
a type of treatment that uses drugs or other substances to identify and attack specific types
of tumor cells that may have less harm to normal cells. Genetic sequencing may help identify
these specific types of tumor cells in patients with non-small cell lung cancer.
Detailed Description
PRIMARY OBJECTIVES:
I. The three month progression free survival (PFS) of patients treated with targeted agents
in the second line setting based on the tumor molecular signature as defined by CancerCode
will be 40% vs 20% with standard cytotoxic chemotherapy.
SECONDARY OBJECTIVES:
I. Response rate (RR). II. Overall survival (OS). III. Proportion of Arm-B patients whose
second line therapy is changed as a result of physician access to CancerCode-50 results.
IV. Concordance of variants identified when sequencing is performed on samples from the same
patient collected at baseline and follow-up time points.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive standard of care therapy based on the discretion of the treating
physician.
ARM B: Patients undergo collection of tissue and blood samples for analysis via sequencing.
Upon disease progression following front-line treatment, patients receive specific targeted
therapy based on the mutational status obtained during sequencing.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 1 year, and then annually thereafter.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Arm A (standard of care treatment) | Active Comparator | Patients receive standard of care treatment based on the discretion of the treating physician. | |
| Arm B (genetic sequencing and targeted therapy) | Experimental | Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing. | |
Eligibility Criteria
Inclusion Criteria:
- Patients with cytologically or histologically confirmed non-small cell lung cancer
(NSCLC) - locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural
or pericardial effusion or pleural implants) OR recurrence after primary surgery or
radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th
edition [Ed])
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1
criteria; previous irradiated tumor is acceptable if there is at least a 20% increase
in the size of the previously irradiated lesion
- Patients must be suitable candidates for treatment with standard regimens; this
includes having adequate hematologic parameters, liver function and renal function
based on labs that are deemed acceptable for treatment by the investigators
- Previous radiation allowed provided that 2 weeks has passed since radiation and/or the
patient has recovered from the side effects
- Availability of archival diagnostic tissue (paraffin tissue block, cytospin block from
a fine needle aspirate, or unstained slides from resected tumor, core biopsy, or fine
needle aspirate) is required
- Able and willing to sign an informed consent and Health Insurance Portability and
Accountability Act (HIPAA) authorization
- Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP
must agree to use effective methods of contraception during active treatment and for
the duration of the study
Exclusion Criteria:
- Prior treatment with any investigational or targeted therapies
- Patients with known activating mutations in the epidermal growth factor receptor
(EGFR) gene or anaplastic lymphoma receptor tyrosine kinase (ALK) or c-ros oncogene 1,
receptor tyrosine kinase (ROS-1) (this test [ROS-1] will be done only on select
patients and at the discretion of treating physicians) translocation positive; the
mutational status of all patients will be determined prior to study entry
- Prior malignancy within the past 3 years other than complete resection of basal or
squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate
cancer after curative therapy
- Prior systemic therapy within 14 days of initiating protocol treatment
- Symptomatic brain metastasis or asymptomatic brain metastasis that are 1 cm or greater
in size; patients with asymptomatic sub-centimeter brain metastasis are eligible
- Uncontrolled or unstable medical or psychiatric co-morbidities which would clearly
limits patients participation
- Current, recent (within 2 weeks of enrollment of this study), or planned participation
in an experimental drug study
- Unstable angina
- Pregnant (positive serum pregnancy test) or breast feeding
- History of any disease that could lead to impaired absorption of drugs
- Inability to comply with study and/or follow-up procedures
- Prior allogeneic bone marrow or organ
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | N/A |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Progression Free Survival |
| Time Frame: | Time from start of second line treatment to time of progression or death, whichever occurs first, assessed at 3 months |
| Safety Issue: | |
| Description: | A chi-square test (one-sided; alpha = .1) will be used to assess the efficacy of treating patients with targeted agents based in the Cancer-Code-50 in the second line setting. For each patient "success" will be defined as being progression free for at least 3 months following initiation of second line therapy. Progression free survival times will be characterized separately by arm using the method of Kaplan and Meier. |
Secondary Outcome Measures
| Measure: | Response Rate Defined by RECIST 1.1 |
| Time Frame: | Up to 2 years |
| Safety Issue: | |
| Description: | The response rate (with 95% two-sided confidence intervals) will be computed separately by arm. One-sided chi-square or Fisher's exact tests (alpha = .1) will be used to evaluate differences in response rates between arms. |
| Measure: | Proportion of Arm B Patients Whose Second Line Therapy is Changed as a Result of Physician Access to CancerCode-50 Results |
| Time Frame: | Up to 2 years |
| Safety Issue: | |
| Description: | To assess the effect of sequencing on clinical practice and decision making the proportion of Arm B patients whose second line therapy is changed as a result of physician access to CancerCode-50 results will be computed. This comparison will be based on information provided by the treating physician before being exposed to the sequencing results, and information obtained from a from post-treatment chart review. |
Details
| Phase: | N/A |
| Primary Purpose: | Interventional |
| Overall Status: | Terminated |
| Lead Sponsor: | Fox Chase Cancer Center |
Last Updated
September 4, 2019
